Arno Therapeutics Appoints Interim CEO

Alexander Zukiwski, M.D., has been appointed interim chief executive officer of Arno Therapeutics, Inc., effective immediately. Dr. Zukiwski will also continue in his role as vice president and chief medical officer.
 
Dr. Zukiwski has more than 19 years of experience in pharmaceuticals and biotechnology, including serving as executive vice president, Clinical Research, and chief medical officer at MedImmune, Inc., as well as positions of increasing responsibility with Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) and Ortho Biotech. Dr. Zukiwski replaces Glenn Mattes, who is leaving the company to pursue other interests.
 
Dr. Arie Belldegrun, chairman of the board, said, “On behalf of the board, we would like to thank Glenn for his contributions to Arno over the last three years. Glenn leaves the company after successfully leading the overall growth of the company, overseeing the progress of our clinical development program while building an outstanding leadership team. We wish Glenn the very best.”
 
Also, Lawrence Kenyon, Arno’s chief financial officer, was appointed chief operating officer, expanding his role in the company’s business-related functions. Mr. Kenyon has 25 years of financial and operations experience in the pharma and biopharma industries.
 
Dr. Belldegrun added, “Alex and Larry bring the necessary leadership experience that is vital to Arno’s continued success. Together with our very talented and experienced management team, Arno is well positioned to move our clinical development programs forward.”